Clinical Trials Directory

Trials / Completed

CompletedNCT02901366

Mass Balance Study of FYU-981

Plasma Concentration, Excretion and Mass Balance Orally Administered 14C-FYU-981 in Healthy Male Subjects

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Fuji Yakuhin Co., Ltd. · Industry
Sex
Male
Age
20 Years – 35 Years
Healthy volunteers
Accepted

Summary

To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of FYU-981 after a single 1 mg oral dose of 14C-FYU-981 in healthy male subjects.

Conditions

Interventions

TypeNameDescription
DRUG14C-FYU-98114C-FYU-981, (Oral single dosing)

Timeline

Start date
2016-09-01
Primary completion
2017-01-01
Completion
2018-07-01
First posted
2016-09-15
Last updated
2018-08-21

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT02901366. Inclusion in this directory is not an endorsement.

Mass Balance Study of FYU-981 (NCT02901366) · Clinical Trials Directory